Observational study / 2011
Higher baseline levels of the advanced glycation end product pentosidine were linked to greater 9-year cognitive decline in older adults.
Researchers prospectively evaluated 920 dementia-free older adults (mean age 74.0 years; 495 with diabetes, 425 with normal glucose) over 9 years to assess the link between baseline urine pentosidine levels and cognitive performance. Over 9 years, participants in the high and mid pentosidine tertiles experienced greater score declines than those in the lowest tertile on the 3MS (7.0, 5.4, and 2.5 point decline, p < 0.001) and DSST (5.9, 7.4, and 4.5 point decline, p = 0.03). High or mid pentosidine levels were associated with higher incident cognitive impairment on the 3MS (24% vs 17%, OR = 1.55; 95% CI: 1.07-2.26) and DSST (31% vs 22%, OR = 1.62; 95% CI: 1.13-2.33). There was no interaction between pentosidine level, diabetes status, and cognitive decline.
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 920 older adults without dementia (495 with diabetes, 425 with normal glucose; mean age 74.0 years)
- What was measured
- Scores on 3MS and DSST tests over 9 years, and incident cognitive impairment
THE PAPER
Advanced glycation end product level, diabetes, and accelerated cognitive aging.
Yaffe K, Lindquist K, Schwartz AV, Vitartas C, Vittinghoff E, Satterfield S, Simonsick EM, Launer L, Rosano C, Cauley JA, Harris T. Neurology, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.